Yu Xianzhe, He Shan, Shen Jian, Huang Qiushi, Yang Peng, Huang Lin, Pu Dan, Wang Li, Li Lu, Liu Jinghua, Liu Zelong, Zhu Lingling
Department of Gastrointestinal Surgery, Chengdu Second People's Hospital, Chengdu, Sichuan, People's Republic of China.
West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
Ther Adv Med Oncol. 2022 Jul 18;14:17588359221110176. doi: 10.1177/17588359221110176. eCollection 2022.
Gastric cancer (GC) is a common malignant tumor, and patients with GC have a low survival rate due to limited effective treatment methods. Angiogenesis and immune evasion are two key processes in GC progression, and they act synergistically to promote tumor progression. Tumor vascular normalization has been shown to improve the efficacy of cancer immunotherapy, which in turn may be improved through enhanced immune stimulation. Therefore, it may be interesting to identify synergies between immunomodulatory agents and anti-angiogenic therapies in GC. This strategy aims to normalize the tumor microenvironment through the action of the anti-vascular endothelial growth factor while stimulating the immune response through immunotherapy and prolonging the survival of GC patients.
胃癌（GC）是一种常见的恶性肿瘤，由于有效治疗方法有限，GC患者的生存率较低。血管生成和免疫逃逸是GC进展中的两个关键过程，它们协同作用促进肿瘤进展。肿瘤血管正常化已被证明可提高癌症免疫治疗的疗效，而这反过来又可通过增强免疫刺激得到改善。因此，确定免疫调节药物与GC抗血管生成疗法之间的协同作用可能会很有意义。该策略旨在通过抗血管内皮生长因子的作用使肿瘤微环境正常化，同时通过免疫疗法刺激免疫反应并延长GC患者的生存期。
